A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• N Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, RFoster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, AS Alva, C Mitchell, SS Shen, SP Lerner, G Sonpavde. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. Accepted to the General Poster Session (Abstract #4586) at the ASCO Annual Meeting, June 1-5 2012, Chicago IL. J Clin Oncol 30, 2012 (suppl; abstr 4586). See abstract.
• Beatrice Knudsen, Noah M. Hahn, Siamak Daneshmand, Edwin M. Posadas, Sambit Muhanty, Seth P. Lerner, Guru Sonpavde. Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC): Hoosier Oncology Group GU07-122. Accepted to the General Poster Session (Abstract #324) at the 2014 Genitourinary Cancers Symposium, January 30 – February 1, 2014, Orlando FL. J Clin Oncol 32, 2014 (suppl 4; abstr 324)
• NM Hahn, BS Knudsen, S Daneshmand, MO Koch, R Bihrle, RS Foster, TA Gardner, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CL Corless, AS Alva, SS Shen, F Huang, A Gertych, GE Gallick, J Mallick, C Ryan, MD Galsky, SP Lerner, EM Posadas, G Sonpavde. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Hoosier Cancer Research Network GU07-122. Urol Oncol 2015 Sep 8. pii S1078-1439(15)00402-0. doi: 10.1016/j.urolonc.2015.08.005. [Epub ahead of print] PMID: 26362343.